MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy

    G. Beck, R. Yamashita, Y. Yonenobu, K. Ikenaka, S. Murayama, H. Mochizuki (Suita city, Japan)

    Objective: The purpose of this study is to examine the modification of tau pathology in brain regions of a patient with progressive supranuclear palsy (PSP)…
  • 2023 International Congress

    Early cortical atrophy is related to depression in Parkinson’s disease

    E. Backman, L. Saari, R. Parkkola, J. Lötjönen, M. Gardberg, V. Kaasinen (Turku, Finland)

    Objective: To investigate depression in relation to medial temporal lobe atrophy (MTA), global cortical atrophy (GCA) and white matter hyperintensities (WMH) in neuropathologically confirmed patients…
  • 2023 International Congress

    Quantifying the impact of sensory tricks on the overall severity of cervical dystonia

    A. Mahajan, D. Gonzalez, G. Stebbins, C. Comella (Chicago, USA)

    Objective: To quantify the impact of sensory trick on botulinum toxin dose and treatment outcomes in cervical dystonia (CD) Background: Sensory tricks are voluntary maneuvers…
  • 2023 International Congress

    Patient perspectives on symptoms and functional impacts to inform a digital assessment of Parkinson’s disease

    B. Fehlmann, A. Thomann, E. Davies, J. Twiss, C. Romano, D. Whalley, M. Mayorga, C. Levy, F. Lipsmeier, W. Popp, T. Kustermann, H. Svoboda, T. Nikolcheva, D. Trundell, M. Lindemann, K. Taylor (demuro)

    Objective: The aim of this study is to map patients’ reports of functional limitations and impacts of Parkinson’s disease (PD) to motor signs captured with…
  • 2023 International Congress

    Orthostatic hypotension and frailty

    A. Ovchynnykova, E. Trufanov (Kyiv, Ukraine)

    Objective: to investigate the relationship between functional class of orthostatic hypotension (FC OH) and frailty index (FI). Background: frailty syndrome (FS) as well as orthostatic…
  • 2023 International Congress

    Assessment of non-motor symptoms of Parkinson’s disease after the repeated courses of the autologous stem cell therapy

    V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

    Objective: To evaluate the influence of the second course of the cell therapy on the dynamics of the non-motor symptoms in patients with PD 6…
  • 2023 International Congress

    Hemiparkinsonism secondary to a cerebral cavernous malformation (CCM)

    M. González Sánchez, B. De-La-Casa Fages, JR. Pérez Sánchez, A. Contreras Chicote, S. Secades García, E. Luque Buzo, Y. Fernández Bullido, G. Lafuente Gómez, O. Mateo Sierra, FJ. Grandas Pérez (Madrid, Spain)

    Objective: To describe a case of secondary parkinsonism of unhabitual cause and complex treatment. Background: Secondary parkinsonism constitutes approximately 15% of all parkinsonism cases in…
  • 2023 International Congress

    An SNCA triplication in a Kazakhstani patient with young-onset Parkinson’s disease

    R. Kaiyrzhanov, C. Shashkin, N. Zharkinbekova, V. Akhmetzhanov, Z. Myrzayev, A. Karimova, S. Aidarov, K. Mok, H. Houlden (Shymkent, Kazakhstan)

    Objective: To report a patient with Parkinson’s disease (PD) from Kazakhstan with a rare structural defect in the SNCA gene. Background: Little is known about…
  • 2023 International Congress

    Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure

    I. Cani, P. Guaraldi, G. Giannini, L. Sambati, G. Barletta, P. Cortelli, G. Calandra-Buonaura (Bologna, Italy)

    Objective: To evaluate the cardiovascular and hemodynamic effect of LD in patients with parkinsonism on chronic LD treatment. Background: Levodopa (LD) is the main treatment…
  • 2023 International Congress

    Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson´s disease

    K. Murtomäki, J. Joutsa, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, M. Eklund, S. Nuuttila, E. Pekkonen, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

    Objective: To assess correlations between gastrointestinal symptoms and dopamine transporter (DAT) changes in striatal and extrastriatal areas in Parkinson´s disease (PD) patients. Background: Gastrointestinal symptoms…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley